ArticleScientific reports2021
Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Artificial intelligence in headache medicine: between automation and the doctor-patient relationship. A systematic review.The journal of headache and pain · 2025Pooled it
- Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.BMC neurology · 2022Trial
- Health-related quality of life and associated factors in Chinese menstrual migraine patients: a cross-sectional study.BMC women's health · 2022Trial
- Changes in Migraine-Related Outcomes and Functioning at 1 Year: Results of the Longitudinal OVERCOME (US) Study.Neurology and therapy · 2026Article
- Cyberchondria in Migraine: The Role of Disease Burden and Medication Overuse.European journal of pain (London, England) · 2026Article
- Article
- The MIND Study: Design, Feasibility, and Baseline Characteristics of a Smartphone-Based Migraine Cohort.medRxiv : the preprint server for health sciences · 2026Article
- Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial.Neurology and therapy · 2026Article
- Occupational Risk for Headache Disorders in Female Registered Nurses. A Retrospective Study.La Medicina del lavoro · 2025Article
- Regional and whole-brain neurofunctional alterations during pain empathic processing of physical but not affective pain in migraine patients.The journal of headache and pain · 2025Article
- Article
- Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study.Headache · 2025Article
- Functional Disability and Psychological Impact in Headache Patients: A Comparative Study Using Conventional Statistics and Machine Learning Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Self-esteem and self-compassion status of migraine patients in Turkey: a multi-center study by Turkish Headache Study Group.Frontiers in neurology · 2025Article
- Anxiety and depression among patients with migraine: A single-center cross-sectional study in Malaysia.PloS one · 2025Article
- Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change.Journal of clinical medicine · 2024Review
- Machine Learning and Wearable Technology: Monitoring Changes in Biomedical Signal Patterns during Pre-Migraine Nights.Healthcare (Basel, Switzerland) · 2024Article
- Urine 5-Hydroxyindoleacetic Acid Negatively Correlates with Migraine Occurrence and Characteristics in the Interictal Phase of Episodic Migraine.International journal of molecular sciences · 2024Article
- Migraine treatment: quo vadis? Real-world data study (2015-2022) in Spain.BMC neurology · 2024Article
- Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying highly disabled patients or at high risk of psychiatric comorbidity is crucial for migraine management. The burden of migraine increases with headache frequency, but the number of headache days (HDs) per month after which disability becomes severe or the risk of anxiety and depression is higher has not been established. Here, we estimate the number of HDs per month after which migraine is associated with higher risk of anxiety and depression, severe disability and lower quality of life. We analysed 468 migraine patients (mean age 36.8 ± 10.7; 90.2% female), of whom 38.5% had ≥ 15 HDs per month. Our results show a positive linear correlation between the number of HDs per month and the risk of anxiety (r = 0.273; p < 0.001), depression (r = 0.337; p < 0.001) and severe disability (r = 0.519; p < 0.001). The risk of anxiety is higher in patients having ≥ 3HDs per month, and those with ≥ 19HDs per month are at risk of depression. Moreover, patients suffering ≥ 10HDs per month have very severe disability. Our results suggest that migraine patients with ≥ 10HDs per month are very disabled and also that those with ≥ 3HDs per month should be screened for anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.